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Background: Zheng represents pattern differentiation in Traditional Chinese Medicine (TCM), as the basic unit and a
key concept in TCM therapeutic theory, is based on the physiology and pathology of TCM. None of the outcome
measurements of atopic dermatitis (AD) are Zheng-specific. The effectiveness of TCM is likely to be underestimated
without a Zheng-related symptom-specific instrument. The aim of this study was to develop an instrument for
measuring the Zheng-related symptom-specific status of patients with AD.
Methods: We followed standard methodology to develop the instrument, including item generation and selection,
item reduction and presentation, and pretesting, and recruited 188 patients with AD involved in a six-center
randomized-controlled trial (ChiCTR-TRC-08000156) to validate the questionnaire. We conducted construct validity,
reliability, and responsiveness analysis. The standardized effect size (SES) and standardized response mean (SRM)
were used to calculate the responsiveness of additional items and the total score for the rating items.
Results: ZRADSQ has 15 items, with 12 rating items and 3 additional items. The 12 rating items fall within three
domains: AD symptoms (n = 6 items); Heat (n = 4 items) and Mood (n = 2 items). Confirmatory factor analysis
provided good support for a three-factor model (d.f. = 51, x2=97.11, RMSEA = 0.07, CFI = 0.96), and the Pearson’s
correlation coefficient between ZRADSQ and Severity Scoring of Atopic Dermatitis (SCORAD) was 0.40 (P < 0.001).
The reliability was also good, with a Cronbach’s alpha value for ZRADSQ of 0.84, a split-half coefficient of 0.75, and a
test-retest reliability coefficient of 0.98. The standardized effect size and standardized response mean were close to
or larger than 1, which indicated moderate to good responsiveness.
Conclusions: The ZRADSQ demonstrates promising reliability, validity, and responsiveness. It can be used to determine
whether Zheng-specific or symptom-specific treatments relieve the symptom that is most bothersome the patient.
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a. Item generation and selection 
Results of literature search for items considered to be TCM 
theory for item generation and selection. 
b. Item reduction and pretesting 
Recruitment of 45 participants for the item reduction, with a 
final 40 participants responding in the pretest. 
c. Item presentation 
A total of 17 items were presented. All items were answered on 
a four-point Likert-type scale except for three items that were 
patient-generated indexes of primary, secondary or new 
occurrences of bothersome symptoms. 
d. Validation of the questionnaire 
Among 188 participants from a clinical trial of atopic 
dermatitis, who also completed SCORAD. 
Figure 1 Flow chart of the study phases.
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Atopic dermatitis (AD) is a commonly occurring chronic
inflammatory skin disease that affects an estimated 10-
20% of children and 1-3% of adults [1]. It is reported
that in the United States the direct cost of AD treatment
may exceed $3 billion per year [2]. Traditional Chinese
Medicine (TCM), as one of the therapeutic concepts of
Complementary or Alternative Medicine (CAM), is be-
coming increasingly popular for the treatment of inflam-
matory skin diseases, primarily atopic dermatitis (AD)
[3], such as herbal medicine, massage, and acupuncture.
A survey found that among patients with AD, 42.5% had
use alternative therapies [4], including herbal remedies,
homeopathy.
Valid and reliable outcome measurements are a pre-
requisite for evidence-based practice [5]. However, no la-
boratory tests have been conducted to adequately assess
disease severity in AD. Consequently, several outcome
measures for AD have been published. Only the Severity
Scoring of Atopic Dermatitis (SCORAD), Eczema Area
and Severity Index (EASI), and Patient-oriented Eczema
Measure (POEM) measures currently perform adequately
[6], but none of these is Zheng specific or Zheng-related
symptom specific.
Zheng, which is also called syndrome or pattern, is a
basic concept in TCM. The effectiveness of TCM largely
depends on whether the treatment is coordinated with
Zheng [7]. Yan et al. evaluated 19 clinical trials and
found that ginseng had a positive effect on participants
with Qi deficiency Zheng (pattern), but a negative effect
on participants without Qi deficiency Zheng (pattern)
[8]. Pattern diagnosis as Zheng differentiates clinical
symptom-complexes, and represents specific conditions
that can be adjusted or reversed by corresponding TCM
therapeutic techniques such as herbal medicine and acu-
puncture. Patients with the same illness may have varying
symptom-complexes because of individual differences in
health, and are managed by TCM Zheng-specific or Zheng-
related symptom-specific therapies [9]. However, without a
Zheng-specific or Zheng-related symptom-specific instru-
ment, the effectiveness of TCM Zheng-specific therapies is
likely to be underestimated.
The aim of this project was thus to develop an instru-
ment for measuring Zheng-related symptom-specific sta-
tus in patients with AD.Methods
We followed standard methodology for instrument devel-
opment, which is divided into the phases of item gener-
ation and selection, item reduction and presentation,
pretesting, and questionnaire validation (see Figure 1).
The item generation phase was based on information
gathered from ancient and modern literature.Item generation and selection
We began our work by searching the literature, both an-
cient and modern, for descriptions of AD Zheng-related
symptoms that could inform our work. We searched two
databases for the modern literature – the Chinese Bio-
medicine Database (CBMdisc, 2003–2008) and the
China Scientific Journals Full-text Database (CSJD, 2003–
2008) – using “dermatitis/atopic” as the subject terms
with all of the subheadings. The keywords used for the an-
cient literature search included TaiLianChuang (胎敛疮),
NaiXuan (奶癣), RuXuan (乳癣), XueFengChuang (血风疮),
SiWanFeng (四弯风), JinYinChuang (浸淫疮), TaiXuan
(胎癣), LianMeiChuang (恋眉疮) and LianMeiChuang
(炼眉疮), which were obtained from twelve textbooks or
books, such as Dermatovenerology of Integrated Trad-
itional and Western Medicine and External Medicine of
Traditional Chinese Medicine. Publications up to 1919
were searched in the Encyclopaedia of Traditional Chinese
Medicine (CD-ROM Updated Version, 2006).
The literatures on Zheng-related symptoms of AD that
formed the basis for the item generation contained 194
articles from modern studies, textbooks, and works, and
294 paragraphs from classical literatures, including
works such as “Discussion of Various Causes of Disease
Periods of Five Days (Sui dynasty)”, “Golden Mirror of
Medicine (Qing dynasty)”, and “Prescriptions for Univer-
sal Relief (Ming dynasty)” (see Figures 2 and 3). Items
from these articles or paragraphs largely overlapped, and
so we grouped them into similar themes. Only items
with a frequency of more than 2% were selected.
Item reduction and pretesting
Experts in dermatology and clinical epidemiology took
part in the process of item reduction and presenting.
27 books related to AD symptoms 
38 books, including textbooks
11 books not referring to AD symptoms 
Experts’ investigation
CBMdisk, CSJD 
Total of 457 papers
290 papers not referring to AD symptoms 
167 papers referring to AD symptoms
Final total of 194 works and papers 
Figure 2 Modern literature search process.
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items, and 3 additional items that were patient-generated
indexes of primary, secondary, and new occurrences of
bothersome symptoms. Forty patients with AD from
the Out-patient department, 2nd Affiliated Hospital of
Guangzhou University of Chinese Medicine, Guangzhou,
responded for the item reduction and initial pretesting
phases. Table 1 shows the demographic characteristics
of these participants. All of the participants met the
Raika and Hanifin AD diagnostic criteria [10] and were
aged between 7 and 25 years old. The participants used
a four-point Likert-type scale to rate their AD symp-
toms for the 15 selected rating items, where 0 = none,
1 =mild, 2 =moderate, and 3 = severe. They were also
asked to report the primary bothersome symptom in
the past week, and any secondary bothersome symp-
toms. At the next visit, the participants were asked to
report whether they had experienced any newly occur-
ring bothersome symptoms.
We conducted descriptive analysis and tested the item
discrimination coefficients for all of the rating items by
dividing the participants into two groups – one group
with larger item scores of more than 27%, and another
group with lower item scores of less than 27% [11-13] –
and used an independent samples t-test to compare the
two groups. If the result was p< 0.05, then the item was5 repeat items removed 
Final total of 71 items  
76 items referring to AD symptoms 
294 items 
TCM ancient literature 
218 items not referring to AD symptoms 
Figure 3 Ancient literature search process.deemed to be good at discrimination; if not, then the item
was deemed to be less discriminative. The item-total cor-
relations for the rating items were also calculated (the
additional items were not included). Items with a low dis-
crimination coefficient or with a low item-total correlation
were eliminated.Item presentation
Base on the results of the item discrimination coeffi-
cients and the item-total correlations, one item was de-
leted. All 17 items (14 rating items and 3 additional
items) emerging from the item reduction were answered
on a four-point Likert-type scale, except for the three
additional items about bothersome symptoms. The par-
ticipants were asked about their symptoms in the past
week, and showed ease of understanding of the items.
There were no ceiling or floor effects for the 14 rating
items. The instrument required less than 9 minutes (an
average of 8.25 minutes) to complete.Validation of the questionnaire
We recruited another sample of patients with AD involved
in a six-center randomized-controlled trial (ChiCTR-
TRC-08000156). All of the participants met the Hanifin
and Rajika AD diagnostic criteria [10], had moderate to
severe AD that had lasted more than one year, and wereTable 1 General information on the participants in the









Atopic disease history Yes 29(72.5%)
Parents with atopic disease history Yes 17(42.5%)
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275 eligibility, 250 patients were included, while 30 pa-
tients did not receive intervention and 14 patients were
dropped out. Among the 206 subjects who completed the
whole period of intervention, 188 patients were per proto-
col. They completed the 17-item initial version of the
Zheng-Related Atopic Dermatitis Symptom Questionnaire
(ZRADSQ) and SCORAD [14]. In the nine-month dur-
ation of the trial, the participants were required to
complete the ZRADSQ and SCORAD at the same time
on baseline, week 4, week 8, and week 12. The ZRADSQ
was self-reported by the patients or reported by their par-
ents if they were less than seven years old.
Statistical analysis of validity and reliability
The face validity was judged by the investigators [15].
For the rating items, confirmatory factor analysis (CFA)
was used to test a model with three domains as initially
designed and to eliminate items or revise the structure
of the questionnaire based on a root mean square error
of approximation (RMSEA) of less than or equal to 0.08
and a comparative fit index (CFI) of equal to or greater
than 0.95 [16]. Using the revised questionnaire, we
evaluated the convergent construct validity by calculat-
ing the Pearson’s correlation coefficients between the
ZRADSQ and SCORAD. We calculated the Cronbach’s
alpha values to investigate the internal consistency of the
ZRADSQ domains [15], using a split-half coefficient
(Unequal-length-Spearman-Brown coefficient) to evalu-
ate the split half consistency. We considered correlations
of more than 0.35 to 0.50 to be moderate, more thanTable 2 Results of the item-total correlation analysis in the it




Q2 Itching accompanied by pain 16.60
Q3 Pain 17.03
Q4 Itching aggravated at night 15.68
Q5 Dry skin 15.45
Q6 Night sweats 17.10





Q12 Mouth dryness 16.88
Q13 Thirst 16.95
Q14 Dark urine 16.98
Q15 Constipation 17.15
*Note: Q6 night sweats was deleted (Corrected Item-Total Correlation = 0.195).0.50 to be strong, less than 0.35 to be weak, and less
than 0.20 to be very weak. We used the Pearson’s correl-
ation coefficient to take repeated measurements in a
sample of 30 pretest patients (part of the sample of 40
individuals) who completed the questionnaire twice
within 48 hours to evaluate the test-retest reliability of
the ZRADSQ. And we used a paired t-test to calculate
the discriminant validity. For the additional items, we
used the standardized effect size (SES) and standardized
response mean (SRM) to calculate the responsiveness
characteristic of two of the additional items and the total
score of the rating items. The SES and SRM were the
two indexes used to judge responsiveness, with a value
close to or larger than 1 indicating moderate to good re-
sponsiveness. We divided the participants into two sub-
groups due to their age, i.e. one subgroup with subjects
equal or less than 7 years old, another larger than 7 years
old. We also calculated the standards association validity
coefficient, Cronbach’s alpha coefficient, split-half coeffi-
cient, paired t-test, SES, SRM respectively in these two
subgroups. We used Lisrel 8.8 (Scientific Software Inter-
national, Inc, Chicago) for the CFA and SPSS for
Windows 17.0 for the other statistical analyses (SPSS,
Inc, Chicago).
Ethics
The validation study design was approved by the Ethics
Committee of the 2nd Affiliated Hospital of Guangzhou
University of Chinese Medicine (i.e. Guangdong Provincial
Hospital of Chinese Medicine), Guangzhou, Guangdong






















Table 3 General information on the participants in the













Atopic disease history Yes 93 49.5






Guangzhou (1st) 70 37.2
Chengdu 31 16.5
Nanjing 29 15.4
Guangzhou (2nd) 13 6.9
Haikou 31 16.5
Luzhou 14 7.5
*Note: Two sites were located in Guangzhou.
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tient was younger than 18 years old, then the form was
signed by the patient’s parents.
Results
Development
Forty participants, from the out-patient department, the
2nd Affiliated Hospital of Guangzhou University of Chinese








Itching accompanied by pain
Burning skin
Insomnia
























Figure 4 Parameter estimate values of the model.Their descriptive characteristics are shown in Table 1. The
number of items was reduced to 17 through statistical ana-
lysis in the item reduction phase (see Table 2). In the dis-
crimination coefficient analysis, the p value was less than
0.05 for all of the items.
Validation
For the 188 per protocol subjects of the trial, forty-eight
percent of the participants were male. The mean age of
the recruited participants was 13.57 years. Table 3 shows
the general information on the participants. Among the
17 items (14 rating items and 3 additional items), the 14
rating items were introduced into the initial CFA model.
Two items, Q3 (pain) and Q8 (fatigue), were eliminated
due to a relatively decreasing amount of RMSEA if they
were removed from the model. The final model with
twelve items and three domains had 51 degrees of free-
dom and a chi-square value of 97.11. The RMSEA of
this model was 0.07, which is less than the cutoff of
0.08, and the CFI was 0.96. All of these results indicate
that the model is valid (see Figure 4). The final version
of instrument, ZRADSQ, was with 12 rating items and 3
additional items.
Tables 4, 5 and 6 shows that the Pearson’s correla-
tions between the ZRADSQ and SCORAD in total
and different age groups were ranged from 0.39-0.47
(P < 0.02).
Reliability
The Pearson correlation coefficient between the first
and repeat measurements was 0.98 (see Table 7). The
total Cronbach’s alpha coefficient was 0.84, with a
range of 0.74-0.89 for the individual domains (see
Table 8), and similar results were obtained in the two
subgroups, i.e. one with participants equal or less than






Table 6 Standards association validity coefficient results
in the validation phase (N = 163, age>7)
Kolmogorov-smirnov Pearson correlation coefficient
Statistic df P Statistic P
ZRADSQ 0.06 163 0.20
0.39 <0.001
SCORAD 0.08 163 0.01
Table 7 Test-retest reliability results in the validation





Statistic df P Statistic df P P
First
measurement




0.13 30 0.20 0.97 30 0.50
Table 8 Cronbach’s alpha coefficient in the validation
phase (N = 188, all ages)
Cronbach’s alpha No. of items
ZRADSQ 0.84 12
AD symptoms 0.75 6
Heat 0.74 4
Mood 0.89 2
Table 9 Cronbach’s alpha coefficient in the validation
phase (N = 25, age ≤ 7)
Cronbach’s alpha No. of items
ZRADSQ 0.89 12
AD symptoms 0.85 6
Heat 0.73 4
Mood 0.94 2
Table 4 Standards association validity coefficient results
in the validation phase (N = 188, all ages)
Kolmogorov-smirnov Pearson correlation coefficient
Statistic df P Statistic P
ZRADSQ 0.06 188 0.06
0.40 <0.001
SCORAD 0.08 188 0.01
Table 5 Standards association validity coefficient results
in the validation phase (N = 25, age ≤ 7)
Kolmogorov-smirnov Pearson correlation coefficient
Statistic df P Statistic P
ZRADSQ 0.17 25 0.08
0.47 0.02
SCORAD 0.13 25 0.20
Table 10 Cronbach’s alpha coefficient in the validation
phase (N = 163, age>7)
Cronbach’s alpha No. of items
ZRADSQ 0.83 12
AD symptoms 0.73 6
Heat 0.74 4
Mood 0.88 2
Table 11 Split-half coefficient in the validation phase






Equal length Unequal length
Part 1 6 0.75
0.75 0.75
Part 2 6 0.77
Part 1: Itching aggravated at night, itching, dry skin, itching accompanied by
pain, burning skin, insomnia.
Part 2: Thirst, mouth dryness, constipation, dark urine, fidgeting, irascibility.
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results for the split-half coefficient of total question-
naire and the two age groups were shown in Tables 11,
12 and 13.Discriminant validity and responsiveness
For both primary and secondary bothersome symptoms,
the ZRADSQ and SCORAD showed significant differ-
ences between the baseline and Week 12 scores, with
SES values ranging from 0.94 to 1.38 and SRM values
ranging from 1.00 to 1.35. However, the SES and SRM
values were smaller in those who were equal or less than
7 years old. (see Tables 14, 15 and 16).Table 13 Split-half coefficient in the validation phase






Equal length Unequal length
Part 1 6 0.73
0.72 0.72
Part 2 6 0.78
Part 1: Itching aggravated at night, itching, dry skin, itching accompanied by
pain, burning skin, insomnia.
Part 2: Thirst, mouth dryness, constipation, dark urine, fidgeting, irascibility.
Table 12 Split-half coefficient in the validation phase






Equal length Unequal length
Part 1 6 0.85
0.91 0.91
Part 2 6 0.74
Part 1: Itching aggravated at night, itching, dry skin, itching accompanied by
pain, burning skin, insomnia.
Part 2: Thirst, mouth dryness, constipation, dark urine, fidgeting, irascibility.
Table 14 Results of the paired t-test, SES, SRM in the validation phase (N = 188, all ages)
Baseline Week 12 Difference between before and after treatment
SES SRM
x− ± SD x− ± SD x− ± SD P T 95% CI
Primary bothersome symptom 6.96 ± 2.22 3.89 ± 2.50 3.06 ± 2.86 <0.001 14.68 2.65 - 3.48 1.38 1.07
Secondary bothersome symptom 6.37 ± 2.34 3.50 ± 2.45 2.87 ± 2.88 <0.001 13.67 2.46 - 3.29 1.23 1.00
ZRADSQ 15.14 ± 6.74 8.78 ± 5.62 6.35 ± 6.29 <0.001 13.84 5.45 - 7.26 0.94 1.01
SCORAD 47.61 ± 15.57 26.85 ± 15.56 20.76 ± 15.34 <0.001 18.56 18.55 - 22.97 1.33 1.35
Table 15 Results of the paired t-test, SES, SRM in the validation phase (N = 25, age ≤ 7)
Baseline Week 12 Difference between before and after treatment
SES SRM
x− ± SD x− ± SD x− ± SD P T 95% CI
Primary bothersome symptom 6.68 ± 1.88 4.04 ± 2.43 2.64 ± 2.03 <0.001 6.49 1.80-3.48 1.40 1.30
Secondary bothersome symptom 6.35 ± 2.15 3.99 ± 2.43 2.36 ± 2.27 <0.001 5.21 1.42-3.30 1.10 1.04
ZRADSQ 15.28 ± 7.86 9.72 ± 5.36 5.56 ± 7.35 <0.001 3.78 2.52-8.60 0.70 0.76
SCORAD 42.87 ± 14.38 26.04 ± 14.50 16.83 ± 15.85 <0.001 5.31 10.29-23.38 1.17 1.06
Table 16 Results of the paired t-test, SES, SRM in the validation phase (N = 163, age>7)
Baseline Week 12 Difference between before and after treatment
SES SRM
x− ± SD x− ± SD x− ± SD P T 95% CI
Primary bothersome symptom 7.00 ± 2.27 3.87 ± 2.52 3.13 ± 2.97 <0.001 13.45 2.67-3.59 1.38 1.05
Secondary bothersome symptom 6.37 ± 2.38 3.42 ± 2.45 2.95 ± 2.96 <0.001 12.72 2.49-3.41 1.24 1.00
ZRADSQ 15.12 ± 6.58 8.63 ± 5.66 6.48 ± 6.14 <0.001 13.48 5.53-7.43 0.98 1.06
SCORAD 48.34 ± 15.66 26.97 ± 15.76 21.36 ± 15.22 <0.001 17.93 19.01-23.72 1.36 1.40
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patients were more likely to report itching (34.73%), dry
skin (21.41%), itching aggravated at night (20.10%), itch-
ing accompanied by pain (9.40%), and fidgeting (3.92%)
than the other items. Only a few patients present other
symptoms, such as red skin, skin are not beautiful to
look at, skin erosion and skin exudation.
Scoring system
The scoring system of this instrument contains two
parts. One is the independent VAS for the primary, sec-
ondary, and new occurrences of bothersome symptoms
for the 3 additional items, range from 0.0 to 10.0, the
higher the worse; the other one is a four-point Likert-
type scale for the 12 rating items, values with 0, 1, 2, 3
representing None, Mild, Moderate, Severe symptoms
respectively, and the sum of them is total score, higher
score indicates worse status.
Discussion
We developed an instrument that evaluates Zheng-related
symptoms for use among patients with atopic dermatitis
(AD) by applying standard methodology and following
an established framework. The 15-item ZRADSQ (see
Additional file 1) shows good face validity, adequate in-
ternal consistency reliability, and good responsiveness indetecting change. The construct validity evaluation indi-
cated correlations with SCORAD were coordinated with
the estimated magnitude and direction.
Some studies on AD measurements using the SCORAD
as the criterion [17], for example, Hon et al. validated the
Chinese version of the Nottingham Eczema Severity Score
have good agreement and correlation with SCORAD [18].
Although SCORAD is a good instrument for AD, it was
also used to be the measurement of efficacy and patient’s
condition in the trials of Complementary or Alternative
Medicine (CAM) domain, such as Traditional Korean
Medicine, TCM and homoeopathic treatment for AD
[19-21], however, a huge difference, especially if underesti-
mated in the mild group, would occur if intensity is mises-
timated when using the SCORAD; Surrogate markers of
disease severity could overcome or supplement shortcom-
ing of clinical scores in AD research [22]. As there are no
other validated instruments for AD patients in TCM area,
we believe that this instrument may be useful in daily clin-
ical practice and scientific research, especially in the area
of Complementary or Alternative Medicine (CAM).
The instrument has 15 items, with 12 rating items and
3 additional items. The 12 rating items fall within three
domains: AD symptoms (n = 6 items), Heat (n = 4 items)
and Mood (n = 2 items). Symptoms in the Heat and
Mood domains are the main symptoms of a kind of
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most frequently occurring patterns in AD in Chinese
medicine [23]. Three symptoms – itching, insomnia and
dry skin – were duplicated in the ZRADSQ and
SCORAD. However, the weight and scaling or calcula-
tion of the items in the two scales are different. In
SCORAD [14], itching and insomnia are measured by a
visual analogue scale (VAS) that ranges from 0 to 10
points for each item, whereas in the ZRADSQ, itching,
insomnia, and dry skin are assessed on a four-point
Likert-type scale. Further, although dry skin is evaluated
with a four-point Likert-type scale in both SCORAD and
the ZRADSQ, it is evaluated by the physician in
SCORAD but is self-reported by patients in the
ZRADSQ. The scaling and calculating methods of these
two scales vary because of differences in the underlying
theory that guided their development. The Pearson’s cor-
relation coefficient between the ZRADSQ and SCORAD
was 0.40, indicating a moderate correlation and implying
that the ZRADSQ is only partially related to SCORAD.
The observed correlations indicate good construct valid-
ity. The internal consistency and split-half consistency
indicate that the ZRADSQ has good psychometric prop-
erties. However, the test-retest reliability is not so robust
due to the short retest timeframe, and the responsive-
ness in the age equal or less than 7 years group is not
good enough.
This study has several limitations. First, for practical
reasons, the sample size for the validation of the ques-
tionnaire was fairly small. And more than half of the
participants (57%) were less than 14 years old which may
potentially limit the generalizability of the ZRADSQ. The
results thus need to be further evaluated in a larger AD
population, and should also be applied in an international
context, including a control group of healthy participants,
as further validation. Second, although the ZRADSQ is a
simple and self-reported instrument, it may be difficult
for patients under seven years old to understand and
complete. We did not evaluate the consistency between
the self-reported and parent-reported questionnaires.
Third, we did not random the order of the instruments’
delivering, and thus could not avoid the possibility that
the results may have been affected by the fixed order in
instruments’ reporting. Fourth, we did not give any defi-
nitions of the terms used in the ZRADSQ. Instead, the
participants were guided to choose the answer for each
item that best represented their feelings or the symp-
toms that they had noticed. This means of obtaining re-
sponses may be more feasible for subjective items than
for objective items. Items such as dark urine or constipa-
tion that can be described objectively may be biased
when reported based on individual perceptions. Finally,
we did not establish a mean score for the instrument in
an AD population, which we leave for future research.Conclusions
We have developed and validated an instrument to assess
Zheng-related symptoms in patients with AD. The instru-
ment demonstrates promising reliability and validity. It is a
simple questionnaire that is easy to understand and
complete, and will thus be a suitable instrument for hospital
or population based research on AD. Especially when the in-
terventions are complementary therapies, it can be used to
determine whether the efficacy or effectiveness of a certain
therapy on AD is connected with the change of TCM symp-
toms, and whether Zheng-specific or symptom-specific treat-
ments relieve the symptom that is most bothersome the
patient. Future work will focus on instrument validation in a
larger population and in an international context.
Additional file
Additional file 1: Zheng-related atopic dermatitis symptom
questionnaire (ZRADSQ).
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